Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: Results from a multicenter study

BMC Cancer

Volumn 9, Issue , 2009, Pages

  Lu, Jade J ^a,c   Yao, Xudong ^a   Zhang, Shilin ^a   Dai, Bo ^a   Shen, Yijun ^a   Zhu, Yao ^a   Ye, Dingwei ^a   Huang, Yiran ^b   Zhang, Hailiang ^a   Dong, Baijun ^b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; SORAFENIB;

ADRENAL METASTASIS; ADULT; AGED; ANEMIA; ARTICLE; ASIAN; BLOOD TOXICITY; BONE METASTASIS; CANCER CONTROL; CANCER GROWTH; CANCER SURVIVAL; CHINESE; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCORTICOGRAPHY; FEMALE; HAND FOOT SYNDROME; HUMAN; HUMAN TISSUE; HYPERTENSION; KIDNEY CARCINOMA; LIVER DYSFUNCTION; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MULTICENTER STUDY; NEPHRECTOMY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; SKIN TOXICITY; SURVIVAL TIME;

EID: 68949199667     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-249     Document Type: Article

References (31)

1. Cohen HT McGovern FJ Renal-cell carcinoma N Engl J Med 2005, 353(23):2477-90 10.1056/NEJMra043172 16339096
2. Law TM Motzer RJ Mazumdar M et al Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma Cancer 1995, 76(5):824-32 10.1002/ 1097-0142(19950901)76:5<824::AID-CNCR2820760517>3.0.CO;2-N 8625186
3. Vogelzang NJ Lipton A Figlin RA Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: An outpatient multicenter trial J Clin Oncol 1993, 11(9):1809-16 8355047
4. Motzer RJ Bander NH Nanus DM Renal-cell carcinoma N Engl J Med 1996, 335(12):865-75 10.1056/NEJM199609193351207 8778606
5. Wilhelm SM Carter C Tang L et al BAY 43-9006 exhibits broad spectrum oral anti-tumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis' Cancer Res 2004, 64:7099-109 10.1158/0008-5472.CAN-04-1443 15466206
6. Ratain MJ Eisen T Stadler WM et al Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 2006, 24(16):2505-12 10.1200/JCO.2005.03.6723 16636341
7. Escudier B Eisen T Stadler WM et al Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 2007, 356(2):125-34 10.1056/ NEJMoa060655 17215530
8. Bell DW Brannigan BW Matsuo K et al Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations: Analysis of estrogen-related polymorphisms Clin Cancer Res 2008, 14(13):4079-84 10.1158/1078-0432.CCR-07-5030 18593984
9. Mu XL Li LY Zhang XT et al Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in Chinese patients with non-small cell lung cancer Clin Cancer Res 2005, 11(12):4289-94 10.1158/1078-0432.CCR-04-2506 15958609
10. Weston MK Moss DP Stewart J et al Differences in breast cancer biological characteristics between ethnic groups in New Zealand Breast Cancer Res Treat 2007, 111(3):555-8 10.1007/s10549-007-9813-3 18026873
11. Chen P Aldape K Wiencke JK et al Ethnicity delineates different genetic pathways in malignant glioma Cancer Res 2001, 61(10):3949-54 11358811
12. Wiencke JK Aldape K McMillan A et al Molecular features of adult glioma associated with patient race/ethnicity, age, and a polymorphism in O6-methylguanine-DNA-methyltransferase Cancer Epidemiol Biomarkers Prev 2005, 14(7):1774-83 10.1158/1055-9965.EPI-05-0089 16030116
13. Stafford HS Saltzstein SL Shimasaki S et al Racial/ethnic and gender disparities in renal cell carcinoma incidence and survival J Urol 2008, 179(5):1704-8 2677163 18343443 10.1016/j.juro.2008.01.027
14. Greene FL Page DL Fleming ID et al American Joint Committee on Cancer (AJCC) Cancer Staging Manual Springer-Verlag, Berlin, Heidelberg New York 6 2002
15. Kaplan EL Meier P Nonparametric estimation from incomplete observations J Am Stat Assoc 1958, 53:457-481 10.2307/2281868
16. Flaherty KT Sorafenib in renal cell carcinoma Clin Cancer Res 2007, 13(2):747s-752s 10.1158/1078-0432.CCR-06-2063 17255304
17. Thatcher N Chang A Parikh P et al Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet 2005, 366(9496):1527-37 10.1016/S0140-6736(05)67625-8 16257339
18. Lynch TJ Bell DW Sordella R et al Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 2004, 350(21):2129-39 10.1056/ NEJMoa040938 15118073
19. Uramoto H Sugio K Oyama T et al Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese Lung Cancer 2006, 51(1):71-7 10.1016/ j.lungcan.2005.08.006 16198442
20. Bellmunt J González-Larriba JL Climent MA et al Sorafenib TARGET trial results in Spanish patients Clin Transl Oncol 2007, 9(10):671-3 10.1007/s12094-007-0120-6 17974528
21. Akaza H Tsukamoto T Murai M et al Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma Jpn J Clin Oncol 2007, 37(10):755-62 10.1093/jjco/hym095 17951335
22. Escudier B Lassau N Angevin E et al Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma Clin Cancer Res 2007, 13(6):1801-9 10.1158/1078-0432.CCR-06-1432 17363536
23. Gollob JA Rathmell WK Richmond TM et al Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer J Clin Oncol 2007, 25(22):3288-95 10.1200/ JCO.2007.10.8613 17664476
24. Ryan CW Goldman BH Lara PN Jr et al Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: A phase II study of the Southwest Oncology Group J Clin Oncol 2007, 25(22):3296-301 10.1200/ JCO.2007.11.1047 17664477
25. Drevs J Konerding MA Wolloscheck T et al The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma Angiogenesis 2004, 7(4):347-54 10.1007/s10456-005-1394-3 15886878
26. Drevs J Hofmann I Hugenschmidt H et al Effects of PTK787/ZK 22 a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model Cancer Res 2584, 60(17):4819-24
27. Karpanen T Egeblad M Karkkainen MJ et al Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth Cancer Res 2001, 61:1786-90 11280723
28. Flanigan RC Salmon SE Blumenstein BA et al Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer N Engl J Med 2001, 345(23):1655-9 10.1056/NEJMoa003013 11759643
29. Strumberg D Awada A Hirte H et al Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumors: Is rash associated with treatment outcome? Euro J Cancer 2006, 42(200):548-56 10.1016/j.ejca.2005.11.014
30. Cheng AL Kang YK Chen Z et al Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 2009, 10:25-34 10.1016/S1470-2045(08)70285-7 19095497
31. Llovet JM Ricci S Mazzaferro V et al Sorafenib in advanced hepatocellular carcinoma N Engl J Med 2008, 359(4):378-90 10.1056/ NEJMoa0708857 18650514